News & Articles

FEATURED ARTICLE

Immunotherapy Target: CD19 Antigen

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals for new treatments in multiple sclerosis and leukemia and a major acquisition in the bispecific antibody space...

Read more

Browse articles by topic:

Optimizing Large-scale Circular RNA Production Process with KACTUS Engineered RNase R

Optimizing Large-scale Circular RNA Production Process with KACTUS Engineered RNase R

March 13, 2025

9 min read

Circular RNA: A type of therapeutic drug modality.  Circular RNA (circRNA) is a class of covalently closed, circular non-coding RNA...

Read more →
Case Study: KACTUS T7 RNA Polymerase Enzyme Demonstrates Superior Performance in Independent Study

Case Study: KACTUS T7 RNA Polymerase Enzyme Demonstrates Superior Performance in Independent Study

February 7, 2025

4 min read

Background The production of high-quality mRNA is critical for a wide range of applications, including gene therapy, vaccine development, and...

Read more →
The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

July 16, 2024

7 min read

Exciting news of mRNA vaccine research against monkeypox has been coming out since the beginning of 2024: February 15, the...

Read more →
Engineered T7 RNA Polymerase to Reduce dsRNA

Engineered T7 RNA Polymerase to Reduce dsRNA

May 24, 2023

1 min read

Our Chief Technology Officer, ManHee Suh, recently presented at the NextGen RNA Summit in Boston, MA his talk on "Engineered...

Read more →
Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

April 23, 2023

2 min read

Contact us to request a quote or test sample!   Following the filings of our GMP-Grade BsaI and GMP-Grade T7...

Read more →
BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

January 4, 2023

2 min read

After successful completion of DMF filings for our CRISPR Cas9 enzyme and Maxnuclease in the first half of 2022, we...

Read more →

Have questions? Get in touch!

support@kactusbio.us

Contact Us